Alto Neuroscience, Cash And Short Term Investments Over Time
| ANRO Stock | 4.41 0.13 3.04% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Alto Neuroscience, Performance and Alto Neuroscience, Correlation. Alto |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alto Neuroscience,. If investors know Alto will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alto Neuroscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.85) |
The market value of Alto Neuroscience, is measured differently than its book value, which is the value of Alto that is recorded on the company's balance sheet. Investors also form their own opinion of Alto Neuroscience,'s value that differs from its market value or its book value, called intrinsic value, which is Alto Neuroscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alto Neuroscience,'s market value can be influenced by many factors that don't directly affect Alto Neuroscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alto Neuroscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Alto Neuroscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alto Neuroscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Cash And Short Term Investments Analysis
Compare Alto Neuroscience, and related stocks such as Crinetics Pharmaceuticals, Enanta Pharmaceuticals, and Amicus Therapeutics Cash And Short Term Investments Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRNX | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 14.2 M | 163.9 M | 118.4 M | 170.9 M | 333.7 M | 334.4 M | 558.6 M | 586.5 M |
| ENTA | 23.3 M | 43.8 M | 101.5 M | 90.8 M | 145.2 M | 210.1 M | 223.7 M | 308.7 M | 335.2 M | 386.6 M | 244 M | 249.2 M | 369.9 M | 248.2 M | 234.2 M |
| FOLD | 24.4 M | 55.7 M | 99.1 M | 82 M | 151.7 M | 214 M | 330.4 M | 358.6 M | 504.2 M | 452.7 M | 483.3 M | 482.5 M | 293.6 M | 286.2 M | 251.3 M |
| CNTB | 339.6 M | 339.6 M | 339.6 M | 339.6 M | 339.6 M | 339.6 M | 339.6 M | 339.6 M | 339.6 M | 339.6 M | 156.7 M | 268 M | 164.6 M | 118.7 M | 167.6 M |
| LGND | 7.6 M | 17 M | 12.4 M | 16 M | 167.3 M | 200.2 M | 141 M | 201.7 M | 764.6 M | 1.1 B | 411.2 M | 341.1 M | 211.9 M | 170.3 M | 177.7 M |
| PASG | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 158.9 M | 304.8 M | 315.8 M | 189.6 M | 114.3 M | 203.2 M |
| ORIC | 42.6 M | 42.6 M | 42.6 M | 42.6 M | 42.6 M | 42.6 M | 42.6 M | 42.6 M | 42.6 M | 89.2 M | 293.6 M | 237 M | 206.3 M | 208.2 M | 197.4 M |
| LYEL | 436 M | 436 M | 436 M | 436 M | 436 M | 436 M | 436 M | 436 M | 436 M | 436 M | 612.6 M | 614.8 M | 640.2 M | 546.2 M | 627 M |
| DSGN | 77 K | 77 K | 77 K | 77 K | 77 K | 77 K | 77 K | 77 K | 77 K | 77 K | 36.1 M | 384.1 M | 330.4 M | 281.8 M | 227.1 M |
| RVMD | 9.1 M | 9.1 M | 9.1 M | 9.1 M | 9.1 M | 9.1 M | 9.1 M | 9.1 M | 69.6 M | 122.8 M | 440.7 M | 577.1 M | 644.9 M | 1.9 B | 1.9 B |
Alto Neuroscience, and related stocks such as Crinetics Pharmaceuticals, Enanta Pharmaceuticals, and Amicus Therapeutics Cash And Short Term Investments description
Short Term Investments is an account in the current assets section of Alto Neuroscience, balance sheet. This account contains Alto Neuroscience, investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Alto Neuroscience, fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.My Equities
My Current Equities and Potential Positions
| Alto Neuroscience, | ANRO |
| Classification | Computers |
| Location | California; U.S.A |
| Exchange | New York Stock Exchange |
null 4.41
Check out Alto Neuroscience, Performance and Alto Neuroscience, Correlation. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience, guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Alto Neuroscience, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.